Phase I/ II study of vemurafenib in patients with unresectable or recurrent melanoma with BRAF V 600 mutations-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Phase I/ II study of vemurafenib in patients with unresectable or recurrent melanoma with BRAF V 600 mutations

Published:2015-04-17 Issue:7 Volume:42 Page:661-666
ISSN:0385-2407
Container-title:The Journal of Dermatology
language:en
Short-container-title:J Dermatol

Author:

Yamazaki Naoya¹,Kiyohara Yoshio²,Sugaya Naofumi³,Uhara Hisashi⁴

Affiliation:

1. Department of Dermatologic Oncology National Cancer Center Hospital TokyoJapan

2. Department of Dermatology Shizuoka Cancer Center ShizuokaJapan

3. Chugai Pharmaceutical TokyoJapan

4. Department of Dermatology Shinshu University School of Medicine Nagano Japan

Publisher

Wiley

Subject

Dermatology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1346-8138.12873

Reference22 articles.

2. Recent advances in melanoma research;Takata M;Shinshu Med J,2007

3. Sentinel lymph node biopsy in Japan

4. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

5. Differential sensitivity of melanoma cell lines with BRAF V600E mutation to the specific Raf inhibitor PLX4032

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Optimal strategy in managing advanced melanoma;The Journal of Dermatology;2023-12-12

2. A phase I study of the safety and efficacy of talimogene laherparepvec in Japanese patients with advanced melanoma;Cancer Science;2022-06-30

3. Safety and Tolerability of BRAF Inhibitor and BRAF Inhibitor-Based Combination Therapy in Chinese Patients With Advanced Melanoma: A Real World Study;Frontiers in Oncology;2021-04-01

4. Targeted Therapy and Immunotherapy for Melanoma in Japan;Current Treatment Options in Oncology;2019-01

5. Systematic review and meta-analysis of prevalence of dermatological toxicities associated with vemurafenib treatment in patients with melanoma;Clinical and Experimental Dermatology;2018-10-02

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3